Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Status:
Recruiting
Trial end date:
2026-02-14
Target enrollment:
Participant gender:
Summary
Phase 1b: To evaluate the safety and tolerability of multiple ascending doses of efavaleukin
alfa in subjects with steroid refractory chronic graft versus host disease (cGVHD).
Phase 2: To evaluate the efficacy of efavaleukin alfa in subjects with steroid refractory
cGVHD as measured by overall response rate (ORR) at 16 weeks according to the 2014 cGVHD NIH
Consensus Criteria.